Novo Nordisk Sues Eli Lilly Over Alleged Misleading Advertising Campaign
Novo Nordisk has filed a lawsuit against Eli Lilly in the US over what it claims is misleading advertising by Lilly regarding the comparative efficacy of their obesity and diabetes drugs. The Danish drugmaker alleges that Lilly's campaign used outdated clinical studies to suggest its tirzepatide outperforms Novo's semaglutide, despite no head-to-head trials at highest doses.
Topics: Advertising Regulation Obesity Drugs Pharmaceuticals